Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Scott Obach

Showing results (51-60 of 193) with videos related to

Pageof 20
Sort By:
Journal of Clinical Pharmacology|December 17, 2004
Examination of 209 drugs for inhibition of cytochrome P450 2C8Robert L Walsky, Emily A Gaman, R Scott Obach
Drug Metabolism and Pharmacokinetics|October 30, 2007
In vitro metabolism of CP-122,721 ((2S,3S)-2-phenyl-3-[(5-trifluoromethoxy-2-methoxy)benzylamino]piperidine), a non-peptide antagonist of the substance P receptorR Scott Obach, Jeannine M Margolis, Michael J Logman
Current Drug Metabolism|June 23, 2007
Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure-activity relationships and relationship to clinical drug-drug interactions and idiosyncratic adverse drug reactionsAmit S Kalgutkar, R Scott Obach, Tristan S Maurer
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|October 14, 2011
Radiolabelled mass-balance excretion and metabolism studies in laboratory animals: are they still necessary?R Scott Obach, Angus N Nedderman, Dennis A Smith
Journal of Clinical Pharmacology|November 15, 2006
Evaluation of 227 drugs for in vitro inhibition of cytochrome P450 2B6Robert L Walsky, Angela V Astuccio, R Scott Obach
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 4, 2012
Statistical methods for analysis of time-dependent inhibition of cytochrome p450 enzymesPhillip Yates, Heather Eng, Li Di, et al.
Clinical and Translational Science|December 28, 2019
Prediction of Metabolite-to-Parent Drug Exposure: Derivation and Application of a Mechanistic Static ModelErnesto Callegari, Manthena V S Varma, R Scott Obach
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 27, 2023
Human Absorption, Distribution, Metabolism, and Excretion Studies: Origins, Innovations, and ImportanceMatthew A Cerny, Douglas K Spracklin, R Scott Obach
Drug Metabolism and Disposition: the Biological Fate of Chemicals|November 18, 2004
Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro studyR Scott Obach, Loretta M Cox, Larry M Tremaine
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 24, 2012
Hydralazine as a selective probe inactivator of aldehyde oxidase in human hepatocytes: estimation of the contribution of aldehyde oxidase to metabolic clearanceTimothy J Strelevitz, Christine C Orozco, R Scott Obach
Pageof 20

Showing results (51-60 of 193) with videos related to

Sort By:
Pageof 20
Journal of Clinical Pharmacology|December 17, 2004
Examination of 209 drugs for inhibition of cytochrome P450 2C8Robert L Walsky, Emily A Gaman, R Scott Obach
Drug Metabolism and Pharmacokinetics|October 30, 2007
In vitro metabolism of CP-122,721 ((2S,3S)-2-phenyl-3-[(5-trifluoromethoxy-2-methoxy)benzylamino]piperidine), a non-peptide antagonist of the substance P receptorR Scott Obach, Jeannine M Margolis, Michael J Logman
Current Drug Metabolism|June 23, 2007
Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure-activity relationships and relationship to clinical drug-drug interactions and idiosyncratic adverse drug reactionsAmit S Kalgutkar, R Scott Obach, Tristan S Maurer
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|October 14, 2011
Radiolabelled mass-balance excretion and metabolism studies in laboratory animals: are they still necessary?R Scott Obach, Angus N Nedderman, Dennis A Smith
Journal of Clinical Pharmacology|November 15, 2006
Evaluation of 227 drugs for in vitro inhibition of cytochrome P450 2B6Robert L Walsky, Angela V Astuccio, R Scott Obach
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 4, 2012
Statistical methods for analysis of time-dependent inhibition of cytochrome p450 enzymesPhillip Yates, Heather Eng, Li Di, et al.
Clinical and Translational Science|December 28, 2019
Prediction of Metabolite-to-Parent Drug Exposure: Derivation and Application of a Mechanistic Static ModelErnesto Callegari, Manthena V S Varma, R Scott Obach
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 27, 2023
Human Absorption, Distribution, Metabolism, and Excretion Studies: Origins, Innovations, and ImportanceMatthew A Cerny, Douglas K Spracklin, R Scott Obach
Drug Metabolism and Disposition: the Biological Fate of Chemicals|November 18, 2004
Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro studyR Scott Obach, Loretta M Cox, Larry M Tremaine
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 24, 2012
Hydralazine as a selective probe inactivator of aldehyde oxidase in human hepatocytes: estimation of the contribution of aldehyde oxidase to metabolic clearanceTimothy J Strelevitz, Christine C Orozco, R Scott Obach
Pageof 20